|
Novartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leader
|
09 April 2018 |
|
Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MS
|
23 March 2018 |
|
Novartis teams up with Harvard to develop next generation biomaterial systems to deliver immunotherapies
|
20 March 2018 |
|
Novartis announces changes to the Executive Committee to support strategic priorities
|
12 March 2018 |
|
Novartis expands alliance with Science 37 to advance virtual clinical trials program
|
09 March 2018 |
|
Novartis' Xolair® recommended in new global chronic urticaria guideline
|
06 March 2018 |
|
Novartis and Pear Therapeutics to develop digital therapeutics for patients with schizophrenia and multiple sclerosis
|
01 March 2018 |
|
Treatment with Novartis' Ultibro® Breezhaler® improved cardiac function in COPD patients with lung hyperinflation
|
22 February 2018 |
|
Novartis forms alliance to develop medicines for treating infectious diarrheal disease
|
16 February 2018 |
|
Advanced Accelerator Applications receives FDA approval for Lutathera® for treatment of gastroenteropancreatic neuroendocrine tumors
|
29 January 2018 |